市場調查報告書
商品編碼
1028274

中國的Lobaplatin市場(2021年∼2025年)

Research Report on China's Lobaplatin Market, 2021-2025

出版日期: | 出版商: China Research and Intelligence | 英文 40 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

中國Lobaplatin自發售以來,從2005年到2019年銷量、銷售額皆有增加趨勢。為2020年,年初COVID-19發生,影響中國的醫療機關功能,中國的Lobaplatin的銷售額減少到4億7,200萬美元,不過,從2016年到2020年的年複合成長率依然達到20.3%。由於中國有效抑制COVID-19,從2021年到2025年,中國的Lobaplatin的銷售額預計慢慢恢復。

本報告提供中國的Lobaplatin市場的相關調查,市場規模和預測,給予市場的影響,開發環境,主要製造商與其市場佔有率,價格等資訊。

目錄

第1章 Lobaplatin的相關概念

  • Lobaplatin的適應症
  • 中國的Lobaplatin市場發展
  • 中國的Lobaplatin的政府核准
  • COVID-19對中國的Lobaplatin市場的影響

第2章 中國的Lobaplatin銷售(2016-2020)

  • 銷售額
    • 中國的銷售額
    • 各地區:中國的銷售額
  • 銷售量
    • 中國的銷售量
    • 各地區:中國的銷售量
  • 各劑型:中國的Lobaplatin銷售(2016-2020)
    • 注射
    • 其他

第3章 中國的主要robapurachinmeka分析(2020)

  • 市場佔有率分析
    • 各銷售額製造商市場佔有率
    • 各銷售量製造商市場佔有率
  • Hainan Changan International Pharmaceutical Co. Ltd
    • 企業簡介
    • 中國的Lobaplatin銷售

第4章 各企業的中國的Lobaplatin銷售價格(2020-2021)

  • Hainan Changan International Pharmaceutical Co.

第5章 中國的Lobaplatin市場預測(2021-2025)

  • 市場開發的影響因素
    • COVID-19對市場的影響
    • 市場成長要素和機會
    • 市場威脅與課題
  • 市場規模的預測
  • 市場趨勢的預測
目錄
Product Code: 2109548

According to IARC of WHO, globally, there were 19.29 million new cases of cancer in 2020, among which 2.26 million were cases of breast cancer, surpassing the 2.2 million cases of lung cancer. Breast cancer has become the most prevalent cancer around the world. For Chinese patients, breast cancer ranks first in the incidence of malignant tumors among women, with about 304,000 cases per year, of which about 3% to 10% of women have distant metastases at the time of diagnosis. Even among early stage patients, 30% to 40% of them can develop into advanced breast cancer. The 5-year survival rate for patients with advanced breast cancer in China is only 20%, and the overall median survival time is 2 to 3 years, which is significantly lower than that in developed countries. the statistics from IARC have also shown that there were 3 million cancer deaths in China in 2020, with 120,000 deaths from breast cancer. The number of new lung cancer cases in China in 2020 reached 820,000, 15%-20% of which were cases of small cell lung cancer. The number of deaths from lung cancer in China in 2020 was up to 710,000, accounting for 23.8% of all cancer deaths. Chronic myelomonocytic leukemia (CMML) is a type of cancer caused by myeloproliferative neoplasm with 1-2 cases per 100,000 people. It accounts for approximately 15% of newly diagnosed adult leukemia cases, and considering that China's population is upwards of 1.4 billion, the number of new CMML cases would be above 20,000 per year, and the number of surviving CMML patients exceeds 100,000.

The anti-cancer mechanism of platinum antitumor drugs can be divided into 4 steps: transmembrane transport, hydration dissociation, targeted migration, and acting on DNA to cause DNA replication disorder, thus inhibiting the division of cancer cells.

According to CRI's market research, there are five types of platinum-based antitumor drugs commonly used in China: first-generation cisplatin, second-generation carboplatin and nedaplatin, third-generation oxaliplatin and lobaplatin. Lobaplatin, 1,2-diammino-methy lcyclobutane-platinum (II) lactate, was developed in Germany. In 2002, China's Hainan Changan International Pharmaceutical purchased the patent right and the production and selling rights in China from ASAT, a German company. In 2005, its lobaplatin production was approved by the NMPA of China and marketed as a new Category I drug. In addition to affecting DNA synthesis and replication, its mechanism also affects the expression of the original tumor gene c-mye which is involved in oncogenesis, apoptosis and cell proliferation. The approved indications for lobaplatin in China are advanced breast cancer, small cell lung cancer and chronic myelomonocytic leukemia (CMML).

According to CRI's market research, since its launch in China, lobaplatin showed an upward trend in sales volume and value from 2005 to 2019. In 2020, the sales value of lobaplatin in China declined to USD472 million due to the outbreak of COVID-19 at the beginning of the year which affected the proper functioning of Chinese healthcare institutions, but the CAGR from 2016 to 2020 was still up to 20.3%.

CRI expects that sales of lobaplatin in China will recover gradually from 2021 to 2025 as the COVID-19 is effectively controlled in the country. And the rising incidence of advanced breast cancer, small cell lung cancer and chronic granulocytic leukemia in China caused by increasing environmental pollution and changing lifestyles will boost the sales of lobaplatin. Generic drugs of lobaplatin are also expected to be available in China in the next few years, which will lower the average sales price of lobaplatin and increase the sales volume.

Topics Covered:

The Impact of COVID-19 on China's Lobaplatin Market

The Incidence of Cancer in China

The Development Environment of Lobaplatin in China

Sales Volume of Lobaplatin in China

Sales Volume and Value of Lobaplatin in China by Region

Major Lobaplatin Manufacturers in China and Their Market Shares

Price of Lobaplatin in China's market

Prospects of China's Lobaplatin Market, 2021-2025

Table of Contents

1 Relevant Concept of Lobaplatin

  • 1.1 Indications for Lobaplatin
  • 1.2 Development of China's Lobaplatin Market
  • 1.3 Governmental Approval of Lobaplatin in China
  • 1.4 The Impact of COVID-19 on China's Lobaplatin Market

2 Sales of Lobaplatin in China, 2016-2020

  • 2.1 Sales Value
    • 2.1.1 Sales Value in China
    • 2.1.2 Sales Value in China by Region
  • 2.2 Sales Volume
    • 2.2.1 Sales Volume in China
    • 2.2.2 Sales Volume in China by Region
  • 2.3 Sales of Lobaplatin in China by Dosage Form, 2016-2020
    • 2.3.1 Injection
    • 2.3.2 Other Dosage Forms

3 Analysis of Major Lobaplatin Manufacturers in China, 2020

  • 3.1 Analysis of Market Share
    • 3.1.1 Market Share of Manufacturers by Sales Value
    • 3.1.2 Market Share of Manufacturers by Sales Volume
  • 3.2 Hainan Changan International Pharmaceutical Co. Ltd
    • 3.2.1 Company Profile
    • 3.2.2 Sales of Lobaplatin in China

4 Sales Price of Lobaplatin of Different Companies in China, 2020-2021

  • 4.1 Hainan Changan International Pharmaceutical Co.

5 Prospects of China's Lobaplatin Market, 2021-2025

  • 5.1 Influencing Factors for the Market Development
    • 5.1.1 The Impact of COVID-19 on the Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

List of Charts

  • Chart Patent Information of Lobaplatin in China, 2016-2020
  • Chart Sales Value of Lobaplatin in China, 2016-2020
  • Chart Sales Volume of Lobaplatin in China, 2016-2020
  • Chart Sales Value of Lobaplatin Injection in China, 2016-2020
  • Chart Sales Value and Volume of Lobaplatin in China by Hainan Changan International Pharmaceutical, 2016-2020
  • Chart Forecast on Sales Value of Lobaplatin in China, 2021-2025
  • Chart Forecast on Sales Volume of Lobaplatin in China, 2021-2025